<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="123">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05159544</url>
  </required_header>
  <id_info>
    <org_study_id>FuSion</org_study_id>
    <nct_id>NCT05159544</nct_id>
  </id_info>
  <brief_title>The FuSion Program: A Prospective and Multicenter Cohort Study of Pan-Cancer Screening in Chinese Population</brief_title>
  <official_title>A Prospective, Multicenter, Noninterventional Cohort Study of Muti-Omics Models for Pan-Cancer Screening</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Singlera Genomics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Singlera Genomics Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The integrative study by Fudan and Singlera for cancer early detection(The FuSion Program )&#xD;
      will evaluate sensitivity,specificity and positive/negative predictive value of the screening&#xD;
      model jointly developed by FuDan University and Singlera in a 2-year follow-up corhort&#xD;
      including 10,000 persons in routine annual physicals from dozens of hospitals. The&#xD;
      multi-omics model for pan-cancer screening will be developed in a 3-year follow-up corhort&#xD;
      including 50,000 natural persons in community containing genetic information of tumor&#xD;
      families, assessment of epidemiological risk factors, tumor markers, proteomics, genomics and&#xD;
      DNA methylation. After optimizing, the ability of this model will be validated in the Taizhou&#xD;
      corhort in reality.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 6, 2021</start_date>
  <completion_date type="Anticipated">January 7, 2024</completion_date>
  <primary_completion_date type="Anticipated">July 6, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To develop a multi-omics model for pan-cancer screening integrating the markers of ctDNA mutation, DNA fragmentation and methylation et al.</measure>
    <time_frame>assessed up to 36 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate sensitivity,specificity,positive/negative predictive value of the screening model in participants taking routine annual physicals</measure>
    <time_frame>assessed up to 24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To validate model's efficacy and clinical value in the diagnosis of cancers in Taizhou cohort.</measure>
    <time_frame>assessed up to 12 months</time_frame>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">60000</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Multi-omics model developing and training arm</arm_group_label>
    <description>Blood samples and individual health information from 50,000 participants in community, who got 3-year follow-up are selected.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multi-omics model validating arm</arm_group_label>
    <description>10,000 participants in routine annual physicals from hospitals will be selected, and they will be followed up for 2 years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multi-omics model evaluating arm</arm_group_label>
    <description>Participants in Taizhou cohort will be selected.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Eligible participants will be recruited from the communities in Taizhou city and medical&#xD;
        centers in different provinces, including normal healthy people, high-risk people, those&#xD;
        with benign disease and malignant diseases.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Take physical examinations in our research centers and have no cancer history;&#xD;
&#xD;
          2. &quot;Population Health tracking Survey - simplified version of the questionnaire&quot; must be&#xD;
             filled according to the research program and an annual physical examination can be&#xD;
             received as follow-up ;&#xD;
&#xD;
          3. Timely feed back the information related to tumor diagnosis in other hospitals to the&#xD;
             investigator during the program;&#xD;
&#xD;
          4. Have no birth plan for the last 3 years;&#xD;
&#xD;
          5. Fully understand the study and voluntarily sign the informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Have been diagnosed with esophageal cancer, gastric cancer, colorectal cancer, liver&#xD;
             cancer, lung cancer, pancreatic cancer, breast cancer (including non-primary, such as&#xD;
             recurrence, metastasis or other complications) and other malignant tumors;&#xD;
&#xD;
          2. Received blood transfusion, transplantation and other major operations within 3&#xD;
             months;&#xD;
&#xD;
          3. Participated in other interventional clinical researchs within 3 months;&#xD;
&#xD;
          4. Pregnant or lactating women;&#xD;
&#xD;
          5. Patients with autoimmune diseases, genetic diseases, mental diseases/disabilities and&#xD;
             other diseases considered unsuitable for the study by the investigator;&#xD;
&#xD;
          6. Due to poor compliance, the researcher judged that the study could not be completed.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xingdong Chen, Ph.D</last_name>
    <role>Study Director</role>
    <affiliation>Fudan University Taizhou Institute of Health Sciences, Taizhou, China</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rui Liu, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Singlera Genomics Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wen Zou, Ph.D</last_name>
    <phone>+8615152621812</phone>
    <email>zouwen@fdtzihs.org.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rui Liu, Ph.D</last_name>
    <email>rliu@singleragenomics.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The First Affiliated Hospital of USTC (Anhui Provincial Hospital)</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Beijing Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Chongqing Medical University</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Guangdong Provincial People's Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Union Hospital affiliated to Tongji Hospital, Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Third Xiangya Hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Xiangya Hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Jiangsu Province Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fudan University Taizhou Institute of Health Sciences, Taizhou, China</name>
      <address>
        <city>Taihou</city>
        <state>Jiangsu</state>
        <zip>225300</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wen Zou, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sichuan Provincial People's Hospital</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>West China Hospital of Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Chen X, Gole J, Gore A, He Q, Lu M, Min J, Yuan Z, Yang X, Jiang Y, Zhang T, Suo C, Li X, Cheng L, Zhang Z, Niu H, Li Z, Xie Z, Shi H, Zhang X, Fan M, Wang X, Yang Y, Dang J, McConnell C, Zhang J, Wang J, Yu S, Ye W, Gao Y, Zhang K, Liu R, Jin L. Non-invasive early detection of cancer four years before conventional diagnosis using a blood test. Nat Commun. 2020 Jul 21;11(1):3475. doi: 10.1038/s41467-020-17316-z.</citation>
    <PMID>32694610</PMID>
  </reference>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>December 2, 2021</study_first_submitted>
  <study_first_submitted_qc>December 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2021</study_first_posted>
  <last_update_submitted>December 2, 2021</last_update_submitted>
  <last_update_submitted_qc>December 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Muti-omics</keyword>
  <keyword>Pan-cancer screening</keyword>
  <keyword>Early detection</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

